Sanofi, GSK Covid-19 Vaccine Begins Major Trials, Aiming for Approval by Year End
May 27 2021 - 2:28AM
Dow Jones News
By Pietro Lombardi
Sanofi SA and GlaxoSmithKline PLC are starting large-scale human
trials of their Covid-19 vaccine candidate, which will involve more
than 35,000 people, and said the vaccine could be approved by the
end of the year.
French Sanofi and U.K.-based GSK said Thursday that the phase 3
study will use two formulations; one will target the original
strain, while the other will target the so-called South African
variant.
"The design of the Phase 3, conducted across a broad diversity
of geographies, also allows evaluation of the efficacy of the
candidate against a variety of circulating variants," the companies
said.
The vaccine candidate may be approved in the last quarter of the
year, depending on the outcome of the study and regulatory reviews.
Production will start in coming weeks, so that the vaccine will be
quickly accessible if it is approved.
A booster study will also start in coming weeks, to evaluate the
vaccine's ability to generate a strong booster response regardless
of initial vaccine platform received.
Write to Pietro Lombardi at pietro.lombardi@wsj.com;
@pietrolombard10
(END) Dow Jones Newswires
May 27, 2021 02:14 ET (06:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
